• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage your publications. Semantic Scholar automatically creates author pages based on data aggregated from public sources and our publisher partners.
  • Tanios S. Bekaii-Saab, Mitch A Phelps, +15 authors Miguel Angel Villalona-Calero
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2011 (First Publication: 10 June 2011)
  • PURPOSE Biliary cancers (BCs) carry a poor prognosis, but targeting the RAS/RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) pathway is of significance.Continue Reading
  • John C. Byrd, Thomas S. Lin, +17 authors Michael R Grever
  • Medicine
  • Blood
  • 2007 (First Publication: 15 January 2007)
  • Despite promising preclinical studies with the cyclin-dependent kinase inhibitor flavopiridol in chronic lymphocytic leukemia (CLL) and other diseases, previous clinical trials with this agent haveContinue Reading
  • Thomas S. Lin, Amy S. Ruppert, +17 authors John C. Byrd
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2009 (First Publication: 10 December 2009)
  • PURPOSE Patients with chronic lymphocytic leukemia (CLL) with high-risk genomic features achieve poor outcomes with traditional therapies. A phase I study of a pharmacokinetically derived schedule ofContinue Reading
  • Wenqing Gao, Peter J Reiser, +4 authors James T Dalton
  • Medicine, Chemistry
  • Endocrinology
  • 2005 (First Publication: 1 November 2005)
  • The partial agonist activity of a selective androgen receptor modulator (SARM) in the prostate was demonstrated in orchidectomized rats. In the current study, we characterized the full agonistContinue Reading
  • Craig C. Hofmeister, Xiaoxia Yang, +18 authors Mitch A Phelps
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2011 (First Publication: 1 September 2011)
  • PURPOSE Multiple myeloma (MM) is an incurable plasma-cell neoplasm for which most treatments involve a therapeutic agent combined with dexamethasone. The preclinical combination of lenalidomide withContinue Reading